InvestorNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Announces Contract for Full Suite of Digital Therapeutic Solutions

DarioHealth (NASDAQ: DRIO), a leader in the global digital-therapeutics (“DTx”) market, today announced its entry into a contract with a U.S. national employer for the company’s full suite of chronic condition management solutions, including diabetes, pre-diabetes, hypertension, musculoskeletal, behavioral health, and digital employee assistance programs. According to the update, enrollment of DarioHealth’s multi-condition suite of chronic condition management solutions is expected to begin in the first quarter of 2022, consistent with the employer’s benefit year. “This new contract continues to validate Dario’s investment in building a comprehensive, multi-condition digital therapeutics platform,” said Erez Raphael, chief executive officer of DarioHealth. “This new employer is the first of many customers in our pipeline seeking an integrated multi-condition solution for some of their highest-cost chronic conditions. Importantly, these full-suite agreements can potentially generate four to six times more revenue than a single condition solution for Dario by expanding both the number of people eligible and the revenue per member.”

To view the full press release, visit https://ibn.fm/AVw0x

About DarioHealth Corp.

DarioHealth is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. DarioHealth offers one of the most comprehensive digital therapeutics solutions on the market — covering multiple chronic conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health within one integrated technology platform. Dario’s next-generation, AI-powered, digital therapeutic platform supports more than just an individual’s disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions, intuitive, clinically proven digital tools, high-quality software, and coaching to help individuals improve health and sustain meaningful outcomes. Dario’s unique user-centric approach to product design and engagement creates an unparalleled experience that is highly rated by users and delivers sustainable results. The company’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology and utilizes a performance-based approach to improve its users’ health. On the path to better health, Dario makes the right thing to do the easy thing to do. To learn more about DarioHealth and its digital health solutions, or for more information, visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.